KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Shares Outstanding (Diluted Average) (2021 - 2025)

Vir Biotechnology's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $138.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 1.67% year-over-year to $138.5 million; the TTM value through Dec 2025 reached $138.5 million, up 1.67%, while the annual FY2025 figure was $138.5 million, 1.67% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $138.5 million at Vir Biotechnology, roughly flat from $138.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $138.9 million in Q3 2025 and bottomed at $132.5 million in Q2 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $135.1 million (2022), against an average of $135.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) decreased 0.5% in 2023 before it increased 1.81% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $133.4 million in 2021, then grew by 1.03% to $134.8 million in 2022, then fell by 0.5% to $134.1 million in 2023, then grew by 1.58% to $136.2 million in 2024, then increased by 1.67% to $138.5 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Shares Outstanding (Diluted Average) are $138.5 million (Q4 2025), $138.9 million (Q3 2025), and $138.4 million (Q2 2025).